drugset / Trial / NCT01269021

An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

NCT01269021

Completed 176 enrolled Zhi-Hong Liu, M.D.
RandomizedParallel-groupOpen-labelTreatment

Summary

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid . Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

Timeline

Start
2010-11
Primary completion
2013-10
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Mofetil Small molecule 1 g
Subject Mycophenolate Mofetil Small molecule 1.5 g
Comparator Prednisone Other / unclassified 0.4 mg/kg
Comparator Prednisone Other / unclassified 0.6 mg/kg
Comparator Prednisone Other / unclassified 0.8 mg/kg
Comparator Prednisone Other / unclassified 1 mg/kg